Gsk (GLAXF) Amortizatization of Intangibles (2011 - 2013)
Gsk (GLAXF) recorded quarterly Amortizatization of Intangibles of $50.2 million in Q4 2013, up 0.82% quarter-over-quarter from $49.8 million in Q4 2012, and up 0.82% on a YoY basis from $49.8 million in Q4 2012.
Gsk (GLAXF) Amortizatization of Intangibles (2011 - 2013) Analysis & Trends
Gsk's Amortizatization of Intangibles history runs 3 years deep, the most recent figure standing at $50.2 million for Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Gsk | - | - | 7.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 50.19 Mn |
| Dec 31, 2013 | 50.19 Mn |
| Dec 31, 2012 | 49.78 Mn |
| Dec 31, 2012 | 49.78 Mn |
| Dec 31, 2011 | 50.29 Mn |
| Dec 31, 2011 | 50.29 Mn |